Tacrolimus ointment for the treatment of steroid-induced rosacea: A preliminary report - 02/09/11
Abstract |
Background: Excessive topical corticosteroid application to facial areas commonly leads to steroid-induced rosacea. This may be a recalcitrant problem that requires months of antibiotic and anti-inflammatory therapy before it resolves. Objective: The purpose of this article is to review the use of tacrolimus ointment, a macrolide anti-inflammatory ointment for the treatment of 3 patients with steroid-induced rosacea. Methods: Three patients with steroid-induced rosacea applied tacrolimus ointment, 0.075% twice daily for 7 to 10 days. Patients were also instructed to avoid topical corticosteroid use and other rosacea-aggravating substances including caffeine, spicy foods, alcohol, hot fluids, and fluoride. Patients were observed for tenderness, erythema, and relief of pruritus. Results: Pruritus, tenderness, and erythema were resolved in all 3 patients after 7 to 10 consecutive days' use of tacrolimus 0.075% ointment in conjunction with avoidance of topical steroids, caffeine, spicy food, alcohol, hot fluids, and fluoride. Conclusion: This preliminary study demonstrates that tacrolimus 0.075% ointment may be effective for patients with steroid-induced rosacea, when combined with avoidance of topical steroid use, as well as avoidance of other agents known to aggravate rosacea (caffeine, spicy foods, alcohol, hot fluids, and fluoride). (J Am Acad Dermatol 2001;44:995-8.)
Le texte complet de cet article est disponible en PDF.Plan
No outside funding sources were used in this study; there is no significant conflict of interest. |
|
Reprint requests: David Goldman, MD, Department of Dermatology, NorthBay Healthcare Medical Group, 1234 Empire St, Fairfield, CA 94533. E-mail: drdavidgoldman@msn.com. |
|
J Am Acad Dermatol 2001;44:995-8 |
Vol 44 - N° 6
P. 995-998 - juin 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?